Judith Tsui, MD, MPH | Division of General Internal Medicine

Professor

Medicine

Director of UW Medical Student Addiction Research Program

Associate Director of the UW Addiction Medicine Fellowship

Faculty Information

Biography

Dr. Judith Tsui sees patients at the Adult Medicine Clinic at Harborview and at Evergreen Treatment Services. She is an internist who is also certified in Addiction Medicine through the American Board of Addiction Medicine since 2013. Dr. Tsui assumed the role of Associate Director for the Addiction Medicine Fellowship at the University of Washington in 2019. In 2020, she founded the UW Medical Student Addiction Research (MedStAR) Program and currently serves as Program Director.

Education & Training:

Princeton University

Princeton, NJ

1991

New York University

New York, NY

1997

Residency

Oregon Health Sciences University

Portland, OR

1998–2000

MPH

Rollins School of Public Health, Emory University

Atlanta, GA

2004

Fellow

University of California

San Francisco, CA

2004–2008

Honors:

Magna Cum Laude, Princeton University

1991

Stanley Foundation Research Award, NYU School of Medicine

1994

Internal Medicine Wards Attending Teaching Award, Emory University School of Medicine

2002

Research paper selected for NIDA “Director’s Report” by Dr. Nora Volkow

2015

Research paper selected for NIDA “Director’s Report” by Dr. Nora Volkow

2016

Outstanding Research Mentor Award, UW Medical School Class of 2017

2019

Nominee, UW School of Medicine Excellence in Mentoring Women Faculty Award

2020

Contact

Email:

tsuij@uw.edu

Research & Clinical Interests

Research Interests:

Opioid use disorder
Stimulant use disorder
Pain
HIV
HCV
People who inject drugs
Community models of care
Mobile Health

Publications

PubMed:

PubMed Bibliography

Publications:

Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–81. PMCID: PMC4506774.
Carey K, Huang W, Linas BP, Tsui JI. Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders. J Subst Abuse Treat. 2016 Jul;66:54–9. PMCID: PMC5097249.
Tsui JI, Lira M, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Edwards RR, Samet JH. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. Drug Alcohol Depend. 2016 Sep 1; 166:26–31. PMCID: PMC4983520.
Tsui JI, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug Alcohol Depend. 2019 Feb 1; 195:114-120. Epub 2018 Dec 26. PMCID: PMC6440747.
Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019 Mar 13; 14(1):11. doi: 10.1186/s13722-019-0139-3. PMCID: PMC6417248.
Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, Leroux BG, Merrill JO. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2019 Nov 18. PMID: 31810594.
Samet JH, Tsui JI, Cheng DM, Liebschutz JM, Lira MC, Walley AY, Colasanti JA, Forman LS, Christin Root C, Shanahan CW, Sullivan MM, Bridden CL, Abrams C, Harris C, Outlaw K, Armstrong WS, Del Rio C. Improving the Delivery of Chronic Opioid Therapy among People Living with HIV: A Cluster Randomized Clinical Trial. [published online ahead of print, 2020 Jul 22]. Clin Infect Dis. 2020. PMID: 32697847.
Tsui JI, Lapham G, Boudreau DM, Johnson E, Binswanger IA, Cunningham CO, Thakral M, Arnsten JH, Saxon AJ, Merrill JO, Samet JH, Bart G, Campbell CI, Bradley KA. Opioid use disorder among persons with Hepatitis C and HIV: Data from 6 health systems. Journal of General Internal Medicine, In press.